Literature DB >> 17900303

T cells stimulated in vitro have a suppressive function but do not contain only regulatory T cells.

E Valencic1, E Piscianz, A Tommasini, M Granzotto.   

Abstract

The generation of regulatory T cells (Tregs) in vitro represents an attractive possibility to set up cellular therapies that could prevent and cure autoimmune disorders. Different methods have been proposed to generate Tregs in vitro and to evaluate their phenotype and function. Moreover, the overlap between generation of activated and regulatory cells could often be underestimated. We showed that in vitro treatment of CD4+ CD25- lymphocytes with different stimuli leads to a good expression of CD25 and forkhead box P3 (FoxP3) on most cells, but to a full Treg phenotype (including CD127 negativity) in only a minor percentage of cells, ranging from 17.38% of cells treated with phytohaemagglutinin (PHA) to 50.91% of cells treated with T cell receptor (TCR) stimulation in association with transforming growth factor (TGF)-beta. Some suppressive activity was demonstrated for T cells activated with all the different stimuli. However, while suppression mediated by TCR/TGF-beta treated T cells was associated with an inhibition of both interleukin (IL)-2 and interferon (IFN)-gamma in the co-culture supernatant, the suppression observed for PHA-activated cells occurred in the presence of large amounts of these cytokines. In conclusion, also taking into account other recent publications, caution should be taken in interpretation of data in the field of regulatory T cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17900303      PMCID: PMC2219374          DOI: 10.1111/j.1365-2249.2007.03502.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  33 in total

1.  Generation ex vivo of TGF-beta-producing regulatory T cells from CD4+CD25- precursors.

Authors:  Song Guo Zheng; J Dixon Gray; Kazuo Ohtsuka; Satoshi Yamagiwa; David A Horwitz
Journal:  J Immunol       Date:  2002-10-15       Impact factor: 5.422

2.  Control of regulatory T cell development by the transcription factor Foxp3.

Authors:  Shohei Hori; Takashi Nomura; Shimon Sakaguchi
Journal:  Science       Date:  2003-01-09       Impact factor: 47.728

3.  Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype.

Authors:  Dat Q Tran; Heather Ramsey; Ethan M Shevach
Journal:  Blood       Date:  2007-07-20       Impact factor: 22.113

4.  The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3.

Authors:  C L Bennett; J Christie; F Ramsdell; M E Brunkow; P J Ferguson; L Whitesell; T E Kelly; F T Saulsbury; P F Chance; H D Ochs
Journal:  Nat Genet       Date:  2001-01       Impact factor: 38.330

5.  JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome.

Authors:  T A Chatila; F Blaeser; N Ho; H M Lederman; C Voulgaropoulos; C Helms; A M Bowcock
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

6.  Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis.

Authors:  Adam P Kohm; Pamela A Carpentier; Holly A Anger; Stephen D Miller
Journal:  J Immunol       Date:  2002-11-01       Impact factor: 5.422

7.  The subpopulation of CD4+CD25+ splenocytes that delays adoptive transfer of diabetes expresses L-selectin and high levels of CCR7.

Authors:  Veronika Szanya; Joerg Ermann; Cariel Taylor; Claire Holness; C Garrison Fathman
Journal:  J Immunol       Date:  2002-09-01       Impact factor: 5.422

8.  X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy.

Authors:  R S Wildin; F Ramsdell; J Peake; F Faravelli; J L Casanova; N Buist; E Levy-Lahad; M Mazzella; O Goulet; L Perroni; F D Bricarelli; G Byrne; M McEuen; S Proll; M Appleby; M E Brunkow
Journal:  Nat Genet       Date:  2001-01       Impact factor: 38.330

9.  Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production.

Authors:  Sarah E Allan; Sarah Q Crome; Natasha K Crellin; Laura Passerini; Theodore S Steiner; Rosa Bacchetta; Maria G Roncarolo; Megan K Levings
Journal:  Int Immunol       Date:  2007-02-27       Impact factor: 4.823

10.  Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression.

Authors:  Silvia Deaglio; Karen M Dwyer; Wenda Gao; David Friedman; Anny Usheva; Anna Erat; Jiang-Fan Chen; Keiichii Enjyoji; Joel Linden; Mohamed Oukka; Vijay K Kuchroo; Terry B Strom; Simon C Robson
Journal:  J Exp Med       Date:  2007-05-14       Impact factor: 14.307

View more
  4 in total

1.  Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses.

Authors:  Marij J P Welters; Gemma G Kenter; Peggy J de Vos van Steenwijk; Margriet J G Löwik; Dorien M A Berends-van der Meer; Farah Essahsah; Linda F M Stynenbosch; Annelies P G Vloon; Tamara H Ramwadhdoebe; Sytse J Piersma; Jeanette M van der Hulst; A Rob P M Valentijn; Lorraine M Fathers; Jan W Drijfhout; Kees L M C Franken; Jaap Oostendorp; Gert Jan Fleuren; Cornelis J M Melief; Sjoerd H van der Burg
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-14       Impact factor: 11.205

Review 2.  Allergy and the nose.

Authors:  G Ciprandi; G Passalacqua
Journal:  Clin Exp Immunol       Date:  2008-09       Impact factor: 4.330

3.  Activation-induced FoxP3 expression regulates cytokine production in conventional T cells stimulated with autologous dendritic cells.

Authors:  Derek J Cavatorta; Hollis N Erb; M Julia Felippe
Journal:  Clin Vaccine Immunol       Date:  2012-08-01

4.  Altered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome.

Authors:  J X Zou; D E Rollison; D Boulware; D-T Chen; E M Sloand; L V Pfannes; J J Goronzy; F Bai; J S Painter; S Wei; D Cosgrove; A F List; P K Epling-Burnette
Journal:  Leukemia       Date:  2009-03-12       Impact factor: 12.883

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.